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Abstract 
Introduction: The aim of this study was to determine the prognostic value of the first urinary 
albumin/creatinine ratio (ACR) for adverse maternal and neonatal outcomes and how it 
relates to other prognostic factors. Material and methods: We performed a retrospective 
cohort study from December 2009 to February 2012 with analysis of demographic, clinical 
and biochemical data from two obstetric day assessment units in hospitals in Southeast 
Scotland. We included 717 pregnant women, with singleton pregnancies after 20 weeks 
gestation, referred for evaluation of suspected pre-eclampsia and having their first ACR 
performed. The ability of ACR to predict future outcomes was assessed in both univariable 
and multivariable logistic regression models. The latter assessed its prognostic value 
independent to (adjusting for) existing prognostic factors. Primary outcome measures were 
maternal and neonatal composite adverse outcomes, and a secondary outcome was gestation 
at delivery. Results: 204 women (28.5%) experienced a composite adverse maternal outcome. 
146 women (20.4%) experienced a composite adverse neonatal outcome. Multivariate 
analysis of log-transformed ACR, demonstrated that a 1-unit increase in log ACR is 
associated with an increased odds of adverse maternal (Odds Ratio 1.60, 95% CI 1.45-1.80) 
and adverse neonatal (Odds Ratio 1.15, 95% CI 1.02-1.29) composite outcomes, and with 
reduced gestational age at delivery (coefficient: -0.46, 95% CI -0.54 to -0.38). Conclusions: 
ACR is an independent prognostic factor for maternal and neonatal adverse outcomes in 
suspected pre-eclampsia. ACR may be useful to inform risk predictions within a prognostic 
model. 
 
Keywords:  
pre-eclampsia, cohort study, ACR, albumin to creatinine ratio, risk factors, prognosis, 
adverse events 
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Abbreviations 
ACR   albumin to creatinine ratio 
BMI   body mass index  
BP  blood pressure 
OR  odds ratio 
RR  risk ratio 
MAP   mean arterial blood pressure 
 
Key Message 
Albumin to creatinine ratio is an independent prognostic factor for maternal and neonatal 
adverse outcomes in suspected pre-eclampsia though the prognostic value appears larger for 
maternal outcomes. Therefore albumin to creatinine ratio could play an important role in 
healthcare research and clinical practice in the future. 
 
Introduction  
Pre-eclampsia is defined as the presence of raised blood pressure (BP; ≥140/90mmHg) after 
20 weeks gestation, in a previously normotensive non-proteinuric patient with one or more of 
the following; significant proteinuria (≥ 0.3g/24hours), maternal organ dysfunction or 
uteroplacental dysfunction (1,2). Suspected pre-eclampsia is the most frequent clinical 
presentation to obstetric units. Pre-eclampsia is associated with severe complications such as 
seizures, stroke, multiple organ failure and perinatal mortality, if not recognised and managed 
properly.  
 
The spot urinary protein to creatinine ratio  and the albumin to creatinine ratio (ACR) have 
been studied in patients with renal disease, diabetes and pre-eclampsia to assess proteinuria. 
Albumin excretion is considered to reflect glomerular damage more accurately than total 
protein excretion, and albuminuria may be a marker of systemic endothelial cell dysfunction 
(3). The majority of international organisations now recommend spot proteinuria tests in the 
assessment of suspected pre-eclampsia. ACR has been shown to be an accurate indicator of 
proteinuria in women with pre-eclampsia (4-6). Despite this evidence the obstetric 
community has not widely adopted the use of ACR as yet and protein to creatinine ratio or 
24-hour urine collection are more commonly employed.  
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As well as being useful in the diagnosis of pre-eclampsia (4,6), ACR has potential to be 
useful in predicting adverse pregnancy outcomes (7,8). New prognostic factors are needed in 
this area (9-12). Prognostic factors can guide clinical decision-making, patient counselling, 
and inform the design and analysis of new trials (10-12). They can also improve prognostic 
models, which produce absolute risk predictions for women based on a set of individual 
characteristics (9). Before including a new factor in a prognostic model, it is important to 
quantify its independent prognostic value over and above existing prognostic factors. Factors 
that add additional (independent) prognostic information are difficult to find, but are 
necessary to improve the discrimination performance of prognostic models (12). 
 
The aim of this study was to examine the prognostic value of baseline ACR (ACR at first 
presentation) to predict maternal and neonatal adverse outcomes in women referred with 
suspected pre-eclampsia There were two objectives: (i) to examine if ACR is prognostic for 
adverse maternal and neonatal outcomes when no other factor is considered (unadjusted 
prognostic effect) and (ii) to evaluate whether ACR is a prognostic factor for such outcomes 
after adjusting for existing prognostic factors (independent prognostic effect).  
 
 Material and methods 
Study Design 
We performed a retrospective cohort study of pregnant women undergoing ACR test in the 
obstetric Day Assessment Units of two hospitals in National Health Service Lothian trust 
between December 2009 and February 2012. The Simpson Centre for Reproductive Health is 
a tertiary referral centre with more than 6,500 deliveries per annum. St John’s Hospital is a 
district general hospital with approximately 2,600 deliveries per annum. Women were 
excluded if they had not delivered by the end of February 2012.  
 
All pregnant women with urinary ACR results were identified from biochemistry database 
(APEX, ApexHealthware). Women were included if they had booked for their pregnancy 
prior to 14 weeks and if they were referred from primary care to the hospital Day Assessment 
Unit with suspected pre-eclampsia (suspected hypertension [generally ≥140/90mmHg] and at 
least 1+ proteinuria on dipstick testing). Women were excluded if they had multiple 
pregnancy, proteinuric renal disease, proven urinary tract infection or if the ACR was 
measured for another indication (for example diabetes). Women who had their first ACR sent 
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prior to 20 weeks of gestation were also excluded as this suggests a chronic hypertensive or 
proteinuric disorder or underlying renal pathology. 
 
We performed systematic review of medical records collecting predefined characteristics 
(demographic and clinical) to maximize accuracy and minimise missing data. We used 
multiple data sources to collect neonatal outcome data, in order to increase confidence that no 
cases of perinatal mortality or significant morbidity were missed.  Data were acquired from 
the maternity electronic patient records database TRAK (supplied by Intersystems) and the 
neonatal unit electronic patient records database BadgerNet (supplied by Clevermed) systems. 
Demographic features were recorded at booking visit, clinical and laboratory data at the time 
of first ACR measurement and subsequent antenatal visits and at delivery, and the outcome of 
mothers and babies were collected on every pregnancy.  
 
ACR measurement taken on first hospital assessment for suspected pre-eclampsia was used 
in the analysis (i.e. follow up measurements were not included). ACR was calculated from 
urine samples in the biochemistry labs of The Royal Infirmary of Edinburgh.  Immunoassays 
(Abbott Architect), turbidmetric and kinetic alkaline picrate (Jaffe) were used to calculate the 
concentrations of albumin and creatinine respectively in the urine sample. From this the 
albumin (mg/L)/urine creatinine (mmol/L) was calculated.  
 
Existing prognostic factors were: gestational age at ACR measurement, essential 
hypertension, pre-existing diabetes, gestational diabetes, social deprivation index, body mass 
index (BMI), mean arterial BP, current smoking status, parity and maternal age recorded 
from the clinical record at booking (< 14 weeks). Deprivation was recorded as social multiple 
index of deprivation [a postcode based Scottish Index of multiple deprivation from 2012 - 
five groups ranging from most deprived index (1) to least deprived index (5)] (13). BMI was 
recorded as [< 18.5, 18.5 − 24.99, 25.0 − 29.99, 30.0 − 34.9, 35.0 − 39.9 and > 40] and mean 
arterial BP(MAP) [diastolic BP+ 1/3 (systolic BP-diastolic BP]. MAP was used in place of 
systolic or diastolic BP, because previous evidence suggests it is a better prognostic factor for 
pre-eclampsia compared to BP measured during the first or second trimester of pregnancy 
(14). Data on development of gestational diabetes (to allow exclusion and diagnosed using 
Scottish Intercollegiate Guidelines network guideline (15)) and gestation at ACR (days) were 
also recorded.  
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The primary maternal outcome was a composite adverse maternal outcome, defined as one or 
more of: use of intravenous magnesium sulphate for seizure prophylaxis, use of intravenous 
anti-hypertensives, admission to intensive care unit / or high dependency unit for 
hypertension, placental abruption, eclampsia or HELLP (Haemolysis, Elevated Liver 
enzymes, low platelets). The primary neonatal outcome was a composite adverse neonatal 
outcome, defined as one or more of: iatrogenic preterm delivery <34 weeks, birth weight 
<5th centile (calculated from sex-specific birth weight centile charts) (16), , abnormal 
umbilical artery Doppler [absent or reversed end-diastolic (ARED) flow ], arterial cord 
pH<7.1, need for ventilation, neonatal or intrauterine death. Secondary outcome was 
gestation at delivery (weeks). 
 
No formal power calculation was performed, and we included all data available over a three-
year time period to maximise sample size. In prognosis research, a typical rule of thumb is 
that at least ten events (cases with the outcome of interest) are required to evaluate every one 
candidate prognostic variable (17). In our study over 200 women had a maternal composite 
adverse outcome, thus the sample size was considered adequate for the analysis performed. 
  
3.9% of women had one or more missing values for data on existing prognostic factors. Due 
to the small proportion missing we considered a complete case multivariable analysis 
sufficient (18).. Thus, only a complete case analysis was performed, and the relatively few 
women with missing data were excluded for the multivariable analysis but included in the 
ACR only analysis. 
 
Primary analyses 
The baseline characteristics of the sample were summarised by primary outcome status with 
differences between groups assessed using unpaired t-tests or Mann Whitney U tests for 
continuous and χ2-tests for binary data. 
 
Univariable and multivariable logistic regression models were used to examine the 
unadjusted and the adjusted (independent) prognostic association of ACR with each binary 
primary outcome. The multivariable analysis adjusted for a pre-defined set of factors that we 
considered to be prognostic factors, as described above . 
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For the continuous variable “ACR” the assumption of linearity of the prognostic effect on the 
log-odds scale was examined using fractional polynomials. Fractional polynomials of degree 
two were used to obtain an appropriate transformation for ACR, for which the linearity 
assumption did not hold (19). This suggested that a logarithmic transformation was needed 
for ACR. Thus, the logistic models estimated the prognostic value of ACR as summarised by 
an (adjusted) odds ratio (OR), giving the (adjusted) relative odds of the outcome for two 
individuals that differ in log-ACR by 1-unit. To avoid deletion of patients with undefined log 
transformed ACR values (log (0)), 0.01 was added across all the entries of ACR following 
transformation of the data. 
 
Similarly, univariable and multivariable models were fitted for the secondary outcome, 
gestation weeks at delivery using linear rather than logistic regression.  
 
For the neonatal composite outcome gestational age at ACR measurement was adjusted for as 
a binary outcome after categorizing to age<34 weeks and age ≥ 34 weeks. This categorization 
was enforced by the clinical team in advance of the analysis as: 1) Women who had the first 
ACR test before 34 weeks represented a group with suspected pre-term pre-eclampsia versus 
women with suspected later onset pre-eclampsia, 2) Pre-term pre-eclampsia is a more severe 
clinical condition and more often associated with neonatal adverse outcome including 
premature delivery, and 3) Part of the composite adverse neonatal outcome is iatrogenic pre-
term delivery prior to 34 weeks. The rationale was based on the existing literature (20-23). 
 
Secondary analysis 
The discrimination performance of the entire multivariable model was summarised to 
ascertain its potential as a prognostic model, using the apparent C statistic [area under the 
receiver operating characteristic (ROC) curve] where 0.5 indicates no discrimination 
(between those with and those without the outcome) beyond chance and 1 indicates perfect 
discrimination. The C-statistic is equivalently defined as the probability that the predicted 
risk for a randomly selected individual with the outcome is higher than that for a randomly 
selected individual without the outcome (24).  
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Sensitivity analysis 
Alongside the univariable and multivariable logistic regression analyses to obtain ORs, 
Poisson regression with robust standard errors was used to obtain (adjusted) risk ratios (RRs). 
The dataset included extreme values (two entries ACR=2000 and one entry where ACR=0). 
Therefore a sensitivity analysis was run to examine the effect of excluding these values.  
 
All analyses were performed in STATA version 12 (StataCorp., College Station, TX,, USA) 
and the regression models fitted using maximum likelihood estimation. 
 
This was a retrospective study on samples already obtained and the study was approved 
through the University of Edinburgh and registered with the University of Edinburgh and 
NHS Lothian on 29/2/2012. No external ethics committee was required. An agreement with 
the data holder was in place to use the data, for the purposes of this study, which were 
anonymous and unlinked.  
 
Results  
941 pregnant women had an ACR performed during the study period.  224 records were 
excluded due to predefined exclusion criteria leaving a cohort of 717 women. Complete data 
(on ACR and existing prognostic factors for the multivariable analysis) was available for 689 
women. Women’s characteristics are detailed in Table 1. The majority of first ACR 
measurements were performed between 35 and 40 weeks gestation (interquartile range 35-40 
weeks, median=37 weeks and standard deviation= 4 weeks). 
 
Adverse maternal outcomes  
204 of 717 included women experienced a composite adverse maternal outcome (28.5%) 
(Table 2). Thirty women had more than one adverse event (n=174 one event, n=26 two 
events, n=4 three events) leading to a total of 238 adverse outcomes.  Supporting Information 
Table S1 shows the maternal characteristics for the women with and without composite 
adverse maternal outcomes. MAP and maternal age at booking were comparable between the 
two groups. There was no significant difference between the two groups regarding essential 
hypertension, gestational diabetes, and smoking or social deprivation index. Univariable 
analysis showed that mean ACR, median gestational age at ACR measurement, mean 
maternal age, pre-existing diabetes and BMI differ between the two outcome groups (Table 
S1).  
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Adverse neonatal outcomes  
146 of 717 neonates experienced a composite adverse neonatal outcome (20.4%) (Table 2). 
Twenty-eight neonates had more than one adverse event (n=118 one event, n=15 two events, 
n=8 three events and n=5 four events) leading to a total of 192 adverse outcomes.   Maternal 
age was comparable between the two groups. There were differences in median gestational 
age at ACR measurement, mean ACR, smoking, BMI and MAP between the groups (see 
Supporting Information Table S2).  
 
Unadjusted and adjusted prognostic value of ACR for maternal and neonatal adverse 
outcomes  
Univariable logistic regression analysis of all 717 women (Table 3) showed that log ACR is 
prognostic both for maternal (OR 1.52, 95% CI 1.38-1.684) and neonatal (OR 1.13, 95% CI 
1.02-1.25) composite adverse outcome. These unadjusted estimates imply that a unit increase 
in log transformed ACR increases the odds of maternal and neonatal adverse outcomes by 
52% and 13% respectively.   
 
Multivariable analysis (based on the 689 women with complete data, Table 3) also showed 
that log ACR is an independent prognostic factor for maternal composite adverse outcome 
(OR 1.60, 95% CI 1.43-1.80) and neonatal composite adverse outcome (OR 1.15, 95% CI 
1.02-1.29). This implies that a unit increase in log transformed ACR, after adjusting for other 
factors increases the odds of adverse maternal composite outcome by 60% and adverse 
neonatal outcome by 15%.  
 
Unadjusted and adjusted prognostic value of ACR for gestation at delivery 
Univariable (coefficient -0.38, 95%CI -0.48 to - 0.27, p<0.001) and multivariable linear 
regression (coefficient -0.46, 95% CI - 0.54 to -0.38, p-value <0.001) shows a prognostic 
effect of log ACR for gestational age at delivery (Supporting Information Table S3). The 
adjusted estimate implies that for every unit increase in log transformed ACR, the average 
gestational age at delivery is decreased by about 0.5 weeks. 
 
Discrimination performance of the multivariate models 
The apparent C-statistic for the multivariable models was 0.76 (95% CI 0.72-0.80) for 
composite maternal adverse outcome and 0.72 (95% CI 0.67-0.77) for composite neonatal 
adverse outcome (Table 3). If ACR is removed then the C-statistic of the multivariable 
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models reduces considerably to 0.67 (95% CI 0.64-0.72) for maternal composite outcome; 
however for the neonatal outcome the C-statistic and its 95% CI barely change.  This 
suggests that ACR is more important, in terms of providing additional discrimination to 
outcome risk predictions, for the maternal outcome. 
 
Sensitivity analysis 
Results from the Poisson model with robust standard errors were consistent with those of 
logistic regression analysis. In both the univariable analysis and multivariable analysis ACR 
still had significant prognostic ability for maternal (unadjusted RR 1.31, 95% CI 1.24-1.39; 
adjusted RR 1.32 95% CI 1.25-1.41) and neonatal outcomes (RR 1.10, 95% CI 1.01-1.19; 
adjusted RR 1.10, 95% CI 1.02-1.19) (Supporting Information Table S4). This implies that, 
after adjusting for other factors, a unit increase in log transformed ACR increases the risk of 
adverse maternal outcome by 32% and fetal adverse outcome by 10%.   
 
The sensitivity analysis, excluding the extreme values (ACR=2000 and ACR=0), did not alter 
any conclusions, for both primary and secondary outcomes (Supporting Information Tables 
S5 and S6). Figures S1 and S2 show the predicted probability of maternal adverse composite 
outcomes for ACR (Figure S1) and log ACR (Figure S2) based on the univariable and 
multivariable models excluding extreme values (ACR=2000 and ACR 0). To illustrate the 
appropriate fit of a linear relationship between logACR and the log-odds of a maternal 
composite outcome, Figure 1 shows the unadjusted linear relationship alongside the observed 
risk.  
 
Discussion 
Based on this retrospective cohort study, we show that log ACR is an independent prognostic 
factor for composite adverse maternal and neonatal outcomes. We suggest that a unit increase 
in log-transformed ACR is associated with a 30% increased risk of maternal adverse 
composite outcome and a 10% risk of neonatal adverse composite outcome (corresponding to 
an increased odds of 60% and 15%, respectively). We also demonstrated that in this 
population a one unit increase in log ACR was associated with a decrease in gestation at 
delivery by approximately 0.5 weeks (approximately three days). 
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Based on the secondary analyses we showed that although ACR is adding prognostic value, 
the overall discrimination performance of the multivariable models was only moderate. Thus 
additional prognostic factors are required in order to improve performance further, for a 
clinically useful model to identify those most likely to have an adverse outcome.  In terms of 
improving discrimination performance (as measured by the C-statistic), ACR appears to be 
more important for maternal outcomes than fetal outcomes.  
 
A systematic review (25) and study that used ORs and appropriate tests on two ACR 
thresholds (26) have already indicated a prognostic ability of ACR for adverse outcomes 
associated with pre-eclampsia. Nonetheless, 3 out of 5 of the studies included in the 
systematic review (25) were conducted 30 years ago with ACR tests having different 
thresholds and performed in heterogeneous populations (7). Previous work is also limited by 
the use of thresholds to categorise (or dichotomise) ACR values (26). Other studies have 
found the degree of proteinuria not to correlate with adverse outcome (6, 27). A major 
strength and uniqueness of our study, was that ACR was analysed as a continuous variable 
(28). .  Categorisation of continuous predictors leads to loss of information, hence to loss of 
power, poor predictive performance and hence poor clinical usefulness (29-31).  It also leads 
to data dredging (to find the ‘best’ threshold) and does not reflect the underlying prognostic 
trend.  
 
A log transformation was identified as the most appropriate scale on which to incorporate 
ACR in the model, suggesting that the effect of a 1-unit increase in ACR depends on the 
actual value of ACR itself.  Other strengths include the use of stored samples to measure 
ACR using standardised measurement methods; the collection of ACR values blind to the 
outcome status; the reasonably large cohort itself, and the very small amount of missing data. 
 
This study had some limitations. The primary outcomes were “composite” to increase the 
power to detect the prognostic ability of ACR. Moreover, the outcomes are objective, and 
clinical severity is similar within each group. However, it is difficult to examine the effect 
size of the prognostic factor of interest for each outcome separately (32). It is instead 
presumed that the effect size is related to all the components of the composite outcome. 
Recommendations suggest that components of composite outcomes should be considered as 
secondary outcomes and that the related results are provided alongside primary analysis. This 
was not possible in this study due to the small number of events in most of the components of 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
the composite outcome. However, these components were carefully selected to ensure that 
they were comparable in magnitude of severity and direction of effect.  
 
A further potential limitation results from the retrospective design of our study, as it is 
difficult to exclude the possibility of intervention bias in observational studies of this type.  
ACR results were available to clinicians, and may have influenced management decisions 
and thereby affected maternal and neonatal outcomes. However, these effects are likely to be 
small, as decision making in women with preeclampsia is based on the whole clinical 
presentation, not just the amount of proteinuria.  
 
We have shown that in women with suspected pre-eclampsia the ACR at presentation is an 
independent predictor of adverse outcome. As an indication as to the potential usefulness of 
ACR in practice, Figure 1 shows how the value of ACR would change the predicted 
probability of an adverse outcome, for a woman whom otherwise had median values of other 
covariates included in our model. However, clinical management of women with pre-
eclampsia is directed by multiple factors e.g. BP control, haematological and biochemical 
parameters, symptomatology and fetal considerations including gestation. Thus there is no 
one single factor that determines management or in particular, intervention via delivery. Our 
data suggest that ACR should be considered within this clinical assessment.  
 
A recent series on prognosis research (9-12) discusses how a single prognostic factor (such as 
ACR) rarely predicts individual outcome risk accurately, and usually does not suitably 
discriminate between high risk and low risk individuals. This is why prognostic models are 
needed, as they utilize multiple prognostic factors in combination to improve individual risk 
prediction accuracy and to better discriminate the underlying risk across individuals (33). 
Future work should focus on identifying further independent prognostic factors for adverse 
outcomes, to further improve the discrimination performance of prognostic models. This may 
include the examination of the prognostic value of multiple measurements of ACR over time. 
In due course, a prognostic model could be developed incorporating a large set of prognostic 
factors (including ACR), followed by internal and external validation to ensure reliability of 
the model predictions. At that stage, its use in clinical decision making could be evaluated, 
for example based on values of high predicted risk that warrant clinical action. 
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Supporting Information legends 
 
Table S1: Maternal characteristics for women who experienced maternal adverse composite 
outcome, values are numbers and percentages unless otherwise stated. 
 
Table S2: Maternal characteristics for neonatal who experienced adverse composite outcome, 
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values are numbers and percentages unless otherwise stated. 
 
Table S3: Linear regression results for the unadjusted and adjusted model for the secondary 
outcome; gestational age at delivery. 
 
Table S4: Poisson regression with robust SE results for ACR (log transformed) for 
unadjusted, adjusted models, where the response is composite maternal/neonatal adverse 
outcome. 
 
Table S5: Logistic regression results with extreme ACR values removed for log transformed 
ACR for unadjusted and adjusted models for the primary outcomes: composite maternal 
adverse outcome and composite neonatal outcome. 
 
Table S6: Linear regression results with extreme ACR values removed for log transformed 
ACR for the unadjusted and adjusted model for the secondary outcome; gestational age at 
delivery. 
 
Figure S1: Graph of the predicted probability of maternal composite adverse outcome (AO) 
against albumin [mg/L] creatinine [mmol/L] ratio (ACR). The adjusted (red) and unadjusted 
(blue) models were fitted using log transformed ACR and the logit was obtained using the 
coefficients from the fitted model multiplied by the means/medians of all other continuous 
adjustment factors, the most common category of the categorical adjustment factors and the 
values of log ACR. 
 
Figure S2: Graph of the predicted probability of maternal composite adverse outcome (AO) 
against the log transformed albumin [mg/L] creatinine [mmol/L] ratio (ACR). The adjusted 
(red) and unadjusted (blue) models were fitted using log transformed ACR and the logit was 
obtained using the coefficient of log ACR from the fitted model multiplied by the values of 
log ACR. 
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Table and figure legends 
 
Table 1: Baseline maternal characteristics (values are numbers and percentages at the presence of a 
given characteristic). 
 
Table 2: Number of maternal and neonatal adverse outcomes. 
 
Table 3: Logistic regression results for unadjusted and adjusted models for the primary 
outcomes: composite maternal and composite neonatal outcomes. 
 
Figure 1. Graph of the predicted probability of maternal composite adverse outcome against 
albumin [mg/L] creatinine [mmol/L] ratio (ACR). The adjusted (red) and unadjusted (blue) 
models were fitted using loge (ln) transformed ACR and the logit was obtained using the 
coefficients from the fitted model multiplied by the means/medians of all other continuous 
adjustment factors, the most common category of the categorical adjustment factors and the 
values of log ACR. 
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Table 1: Baseline maternal characteristics (values are numbers and percentages at the presence of a 
given characteristic)  
 
Characteristic Participants (N=717) 
Maternal age at delivery (years), mean (SD) 29.93 (6.06) 
Booking Characteristics: - 
Nulliparity 
 
57.18% 
Essential hypertension 9.34% 
Pre-existing diabetes 2.79% 
Current smoker 15.85% 
Scottish Index of Multiple Deprivation: 
1 (most deprived) 
 
21.51% 
2 22.63% 
3 20.39% 
4 15.39% 
5 (least deprived) 20.11% 
Body mass index: 
<18.5 
 
2.32% 
18.5-24.99 33.48% 
25.0-29.99 28.55% 
30.0-34.9 20.14% 
35.0-39.9 9.71% 
>40 5.80% 
Booking systolic BP, mean (SD) 115.26 (12.48) 
Booking diastolic BP, mean (SD) 69.78 (9.81) 
Booking mean arterial BP, mean (SD) 84.94 (9.95) 
Development of Gestational Diabetes 3.35% 
Gestational age at ACR test (weeks), median   (IQR) 37.43 (35.0-39.14) 
ACR result (mg/mmol), median (IQR) 4.40 (1.40-23.60) 
Gestational age at delivery (weeks), median  (IQR) 
 
39.43 (38.00-40.43) 
Abbreviations: SD standard deviation, IQR interquartile range; BP blood pressure; HDU high dependency unit; 
ICU intensive care unit; HELLP hemolysis elevated liver enzymes low platelet count syndrome  
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Table 2: Number of maternal and neonatal adverse outcomes  
 
 
Maternal adverse outcomes (Total n=238) Values are numbers 
Use of magnesium sulphate 12 
Use of intravenous antihypertensives 15 
Admission to HDU or ICU for hypertension 196 
Abruption 7 
Eclampsia 0 
HELLP 8 
Neonatal adverse outcomes (Total n=192)  
Iatrogenic preterm delivery < 34 weeks 33 
Birth weight <5th centile 98 
Abnormal Dopplers (AEDF or REDF) 11 
Arterial cord pH < 7.1 12 
Need for ventilation 32 
Intrauterine death 5 
Neonatal death 1 
Abbreviations: HDU high dependency unit; ICU intensive care unit; HELLP hemolysis elevated liver enzymes 
low platelet count syndrome, AEDF absent end-diastolic flow; REDF reversed end-diastolic flow. 
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Table 3: Logistic regression results for unadjusted and adjusted models for the primary outcomes: composite maternal and composite neonatal outcomes 
 
                                                                         Composite maternal adverse outcome Composite neonatal adverse outcome 
Model Variable OR (95% CI) p value ROC* OR (95% CI) p value ROC* 
unadjusted ACR** 1.52 (1.38 - 1.68) <0.001 0.70 (0.66 - 0.74) 1.13 (1.02 - 1.25) 0.022 0.557 (0.504 - 0.610) 
adjusted ACR** 1.60 (1.42- 1.80) < 0.001 
 
0.76 (0.72 - 0.80) 1.15 (1.02 - 1.29) 0.025 0.718 (0.668 - 0.760) 
 
gestational age at 
ACR 0.88 (0.83 - 0.92) < 0.001   0.25 (0.16 - 1.29) < 0.001 
 
 
maternal age 1.04 (1.08 - 1.08) 0.019   0.99 (0.95 - 1.02) 0.505 
 
 
essential hypertension 0.78 (0.38 - 1.60) 0.505   1.62 (0.79 - 3.33) 0.19 
 
 
pre-existing diabetes 0.68 (0.12 - 3.72) 0.655   1.77 (0.40 - 7.88) 0.452 
 
 
gestational diabetes 1.02 (0.38 - 2.77) 0.964   0.73 (0.19 - 2.77) 0.64 
 
 
smoking 0.85 (0.50 - 1.45) 0.55   1.94 (1.16 - 3.26) 0.012 
 
 
nulliparity 0.96 (0.66 - 1.40) 0.826   1.16 (0.77 -1.75) 0.471 
 
 
social deprivation 
index   
 
  
   
 
1 1 
 
  1 
  
 
2 0.80 (0.46 - 1.41) 0.451   0.95 (0.53 - 1.72) 0.876 
 
 
3 1.10 (0.63 - 1.92) 0.73   0.78 (0.42 - 1.45) 0.437 
 
 
4 0.623 (0.33 - 1.19) 0.152   0.78 (0.39 - 1.55) 0.473 
 
 
5 0.424 (0.26 - 0.80) 0.008   0.84 (0.43 - 1.62) 0.603 
 
 
body mass index   
 
  
   
 
< 18.5 1 
 
  1 
  
 
18.5 -24.99 1.06 (0.32 - 3.50) 0.93   0.21 (0.07 - 0.64) 0.006 
 
 
25.0 - 29.99 1.47 (0.44 - 4.93) 0.535   0.12 (0.04 - 0.38) < 0.001 
 
 
30.0 - 34.9 0.70 (0.20 - 2.48) 0.581   0.11 (0.03 - 0.37) < 0,001 
 
 
35.0 - 39.9 0.50 (0.13 - 1.98) 0.321   0.16 (0.04 - 0.57) 0.005 
 
 
> 40.0 0.56 (0.13 - 2.39) 0.434   0.09 (0.02 - 0.41) 0.002 
 
  
mean arterial blood 
pressure 1.02 (1.00 - 1.05) 0.041   0.99 (0.97 - 1.01) 0.381   
 
ROC receiver operating characteristic; * C statistic; ** log transformed ACR (albumin creatinine ratio) 
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